CorMedix Reports Q3 2026 Revenue of $54.5 Million and Net Loss of $14.7 Million
CorMedix reported Q3 2026 revenue of $54.5M, down from $104.3M YoY, and a net loss of $14.7M. Adjusted EBITDA was $3.1M. The company maintained full-year revenue guidance and narrowed adjusted EBITDA guidance. CorMedix agreed to acquire Heron's assets, expecting $125M-$150M in 2027 revenue. The FDA accepted a supplemental application for REZZAYO. DefenCath sales were affected by pricing changes.
How this was made
The 30-second read
Why it matters
The earnings miss and guidance reaffirmation suggest short‑term weakness, but the acquisition and pending FDA decision may offer future upside.
Market read
Primary disclosure of earnings and acquisition; relevant for traders in biotech and small‑cap equities.
What to watch
Potential FDA approval for REZZAYO indication expansion could provide a catalyst not reflected in the immediate earnings reaction.
Background
CorMedix reported a steep decline in Q3 revenue and a net loss, while maintaining full‑year revenue guidance and announcing an acquisition of Heron assets.
Ticker impact
CorMedix disclosed Q3 2026 revenue of $54.5M, down 48% YoY, and a net loss of $14.7M, plus guidance and acquisition details.
downward pressure as investors price in weaker revenue and net loss
The sharp revenue decline and net loss are fresh, material facts that typically trigger a sell‑off in small‑cap biotech stocks.
Market effects
May dampen sentiment for the broader biotech and medical device sector as investors reassess revenue forecasts.
Limited to U.S. small‑cap biotech investors; no broader regional effect.
Minimal global impact beyond niche investors tracking CorMedix.
Counterpoint
If the Heron acquisition delivers the projected $125‑$150M revenue boost in 2027, the stock could rebound on long‑term upside.
Key entities
- companyCorMedix Inc.
Biotech firm reporting Q3 2026 results.
- companyHeron
Target of CorMedix's pending asset acquisition.
